Ixekizumab reduces erosion and increases backfill in the sacroiliac joints of patients with radiographic axial ...

Celltrion, a major Korean biopharmaceutical firm, said Tuesday that its two new biosimilars for bone disease treatment, Stoboclo and Osenvelt, have obtained approval from the United States.

For patients with a rare genetic disorder that turns their muscles into bone, there is new hope. The disease is […] ...

Naxitamab demonstrated clinically meaningful efficacy with manageable safety in patients with relapsed/refractory high-risk neuroblastoma and residual disease in bone/bone marrowNEW YORK, March 03, ...